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ABSTRACT
Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for
endometrial protection. International guidelines on menopausal hormone therapy (MHT) do not specify
on progestogen type, dosage, route of application and duration of safe use. At the same time, the debate
on bioidentical hormones including micronized progesterone increases. Based on a systematic literature
review on micronized progesterone for endometrial protection, an international expert panel’s recom-
mendations on MHT containing micronized progesterone are as follows: (1) oral micronized progesterone
provides endometrial protection if applied sequentially for 12–14 days/month at 200mg/day for up to 5
years; (2) vaginal micronized progesterone may provide endometrial protection if applied sequentially for
at least 10 days/month at 4% (45mg/day) or every other day at 100mg/day for up to 3–5 years (off-label
use); (3) transdermal micronized progesterone does not provide endometrial protection.
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The steroid hormone progesterone plays a key role in female
reproduction1. For therapeutic reasons, micronized progester-
one (MP) can be used for endometrial protection when estro-
gens are applied in menopausal women with an intact
uterus2. However, there is considerable debate about whether
and at which dosage MP provides effective endometrial pro-
tection if applied orally, vaginally, or transdermally3. To dis-
cuss various topics on MP, an international expert meeting of
gynecological endocrinologists from the German-speaking
countries Austria, Germany and Switzerland was held in April
2015 aiming to provide scientifically proven statements on
MP treatment in peri- and postmenopausal women, based on
a systematic literature search and discussion of the results.
Endometrial protection by MP will be the first topic of the
planned series.
Material and methods
A systematic literature search was performed using databases
(Medline (Pubmed), Biosis (Medpilot) and Cochrane (Cochrane
Library)), clinical trial registers (www.clinicaltrialsregister.eu,
www.clinicaltrial.gov, http://apps.who.int/trialsearch/), and the
experts’ own literature collection). Searches were performed
using a combination of keywords and Mesh-terms and text
words related to ‘‘(post-/peri)menopause’’ or ‘‘hormone/estro-
gen replacement therapy’’, ‘‘progesterone’’, ‘‘endometrial
cancer/neoplasm/hyperplasia’’ or ‘‘endometrial biopsy’’ or
‘‘endometrial proliferation/atrophy’’. Estrogen dosages were
classified as high-dose, standard-dose, low-dose and ultra-
low-dose by the expert group according to the definition of
the International Menopause Society4. No time restriction was
applied. The selection process involved a pre-selection via
title and/or abstracts by two independent reviewers (A.L., B.H.)
based on the PICO criteria (Table 1). Discrepancies between
the reviewers were discussed and resolved by consensus.
Included abstracts were ordered as full articles. The selec-
tion process for full articles was performed accordingly.
Meta-analyses and systematic reviews were searched for
secondary literature. The final eligibility assessment and
evaluation of the studies’ quality were performed by the
expert group (P.S., J.N., L.W.)
Results
Of 1028 hits, 40 studies were selected for the systematic
review and expert panel’s discussion5–45.
Oral application of MP
The effect of oral MP on the endometrium has been assessed
by transvaginal ultrasound (TVUS)5,6,10,16,21, endometrial
biopsy10–26 and endometrial cancer incidence7–9 (Table 2).
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Endometrial thickness
Endometrial thickness measured by TVUS was assessed in
postmenopausal women in one 3-year, placebo-controlled,
randomized, controlled trial (RCT) (n¼ 167)21 and two 1-year
RCTs (n¼ 100) with head-to-head comparisons5,6. Participants
received continuous, transdermal estradiol (E2) (2521–505,6 lg/
day) which was sequentially combined with either different
oral progestogens (medroxyprogesterone acetate (MPA),
nomegestrol acetate (NOMAC), dydrogesterone (DYD), MP)6,
MP applied orally or vaginally at different dosages (100 or
200mg/day)5 or oral MP 100mg/day for 2 weeks every 6
months (extended cycle)21. In those studies with head-to-
head comparisons, there were no significant group differen-
ces for endometrial thickness at baseline and after 12
cycles5,6. When comparing the baseline endometrial thickness
with that at study closure, there was either no change
(extended cycle regimen at oral MP 100mg/day21, sequential
regimen at vaginal MP 200mg/day5), or a significant
increase5,6. Another two small, non-controlled studies using
either oral MP 200–300mg/day for 10 days per month16 or
100mg/day for 23 days per month10 reported no change10 or
an endometrial thickness of less than 2mm after 1 year16.
The method of endometrial thickness assessment was
described by two authors only5,6 using the maximal thickness
of the endometrium in the longitudinal plane of the uterus.
Endometrial histology
Endometrial biopsies were performed in 17 studies10–26 of
which eight were RCTs12,13,15,17,18,21,22,24 including two pla-
cebo-controlled RCTs15,21. Endometrial biopsy procedure was
described by all but six authors12,13,16,20,21,25. The majority
either used a pipelle de Cornier14,15,18,22,24,26 or Novak’s cur-
ette14,15,18,22,26. Others used a needle aspiration (pistolet
method)23, vabra suction curettage10,11,15,19 or performed a
conventional dilatation and curettage17,19. A hysteroscopy
was only performed in one study if no tissue was obtained20.
The sample size ranged from 1716 to 59615 women being
postmenopausal in all but one study16. Treatment duration
ranged from 4 months12,24 to 5 years20. Conjugated equine
estrogens (CEE) were the most common estrogen component
of menopausal hormone therapy (MHT) while others used
17b-estradiol. Estrogen dosage was either high-dose14,17,19,
standard-dose10–16,18,20,22–26, low-dose25 or ultra-low-dose21.
Estrogens were applied either orally or transdermally. MP was
examined either at different dosages ranging from 50mg/
day12, 100mg/day10–12,14,19,21,24–26, 200mg/day9,13,15–20,22,23,
300mg/day14,16,17,19,24 to 400mg/day24 or compared to other
progestins (intrauterine levonorgestrel (LNG)23, oral chlormadi-
none acetate (CMA)18,22, oral MPA15,16). The regimen of com-
bined MHT differed, ranging from continuously combined
MHT (28 days per cycle/whole month), intermittently com-
bined MHT (25 days per cycle followed by a 5-day hormone
break) to sequentially combined MHT (continuous estrogen
therapy combined with a progestogen for 10–14 days per
cycle/month). Endometrial biopsies were taken at the end of
all trials and also at baseline in all but four studies14,19–21.
Evaluation of tissue biopsies differed tremendously.
Histomorphology was the most common method used to dif-
ferentiate between proliferative, secretory and atrophic endo-
metrium10–14,16–20,22–26, and, if applicable, normal, hyperplastic
and cancerous endometrium10,11,15,19–21,24. Treatment success
may be defined as yielding an atrophic, inactive or secretory
endometrium whereas treatment failure corresponds to a pro-
liferative endometrium response or hyperplasia22. In addition,
some investigators assessed histomorphometry17, mitotic
count14,26, mitotic index20, DNA synthesis26, proliferation
index (MIB)24, or used transmission electron microscopy and
biochemistry markers19.
Treatment success by oral MP was reported by 11 stud-
ies10–14,16,18,19,22,24,25. Seven studies used a continuous11,12,16
or intermittent10,14,24,25, and four studies a sequential13,18,19,22
MHT regimen. Treatment success was achieved by MP
100–400mg/day if an intermittent MHT regimen was
applied10,12,14,16,24,25. However, absolute numbers ranged
between 3.8% (MP 100mg/day)14 and 100% (MP 200mg/
day)12 for atrophic, and between 0% (MP 200mg/day)12 and
64% (MP 400mg/day)24 for secretory endometrium, while a
proliferative or mildly active endometrium was found in 0%
(MP 100–200mg/day)12 to 23.1% (MP 100mg/day)14.
Accordingly, treatment success was achieved with a sequen-
tial MHT regimen if MP 200–300mg/day was applied13,18,19,22.
In detail, the endometrium was found to be atrophic in
20.8%22 to 56% (MP 200mg/day)13, secretory in 62.5% (MP
200mg/day)18,22 to 83% (MP 300mg/day)19 and proliferative
in 8.3%22 to 31%13 (MP 200mg/day). In contrast, other studies
found an insufficient endometrial transformation if oral MP
was applied intermittently or continuously at 100–200mg/
day23,26 or sequentially at 100–300mg/day17,19,20. The hetero-
geneity of results and their interpretation by the authors may
be attributed to the differences between cohorts, study
designs, endometrium evaluation techniques, thresholds for
treatment success, and also to the lack of sufficient correl-
ation between histomorphology and endometrial safety. For
example, the lack of complete glandular and stromal proges-
tational changes has not been found to be associated with
any detectable impairment in antiproliferative effects.
Table 1. Literature search strategy (PICO criteria); status March 2015.
E1 Population/Patient All (post/perimenopausal) women
(natural or surgical menopause)
using systemic estrogen replace-
ment therapy (estradiol or conju-
gated equine estrogen; estriol and
estrogen were excluded)
E2 Intervention Progesterone (natural), exogenously
administered on oral, transdermal
or vaginal route; duration of study
at least 3 months; in humans
E3 Comparison/control Synthetic progestogens, placebo, no
comparison




rial transformation or atrophy
E5 Article type Clinical studies, observational/epi-
demiological studies (meta-analy-
ses and systematic reviews were
included in order to search for sec-
ondary literature)






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Thus, the inhibition of endometrial proliferation may be disso-
ciated from secretory maturational changes20 and therefore a
complete secretory maturation may not be required for the
prevention of hyperplasia14. Jondet and colleagues even
stated that the histological classification using proliferative
and secretory items does not represent the physiological
aspects seen in normal cycles but rather indicates whether
the pathologist is able to detect any progestogenic action18.
That said, it might be more revealing to assess the preva-
lence of endometrial hyperplasia in endometrium biopsies.
Two small (n¼ 40–50)10,11,19, one short (4 months)24 and one
study using an extended cycle regimen (MP every 6
months)21 reported one case with (simple) hyperplasia
each21,24, or an 1% increase of the prevalence of simple
hyperplasia10,11, respectively, using a sequentially19 or quasi
continuously combined MHT7,8 with MP 100mg/day. In con-
trast, the study with the longest intervention (5 years) did not
find any case of endometrial hyperplasia or carcinoma in
women having applied an 17b-estradiol (E2) patch sequen-
tially combined with MP 200mg/day20. However, there were
only 53 endometrial biopsies with adequate tissue in 153
women completing the study. Thus, the largest study to date
(n¼ 596) is the placebo-controlled RCT Postmenopausal
Estrogen/Progestin Interventions Trial (PEPI) with a 3-year
intervention phase using a sequentially combined MHT with
MP 200mg/day among others15. In this study, all combined
MHT regimens were effective in preventing hyperplasia com-
parable to placebo.
Endometrial cancer incidence
Endometrial cancer incidence in respect to MHT containing
oral MP was assessed by two prospective cohort studies, the
European Prospective Investigation into Cancer and Nutrition
study (EPIC)7 and the E3N8, with E3N being the French cohort
of EPIC. The sample size ranged from 65 6308 to 115 4747
postmenopausal women; the mean follow-up was 9.07 and
10.88 years, respectively. A self-administered questionnaire
containing information on MHT use was sent to participants
once at baseline7 or every 2–3 years8. Within the E3N cohort,
a woman who successively took different types of MHT simul-
taneously contributed to each category. The study designs
did not include gynecological examinations. Information on
the type of estrogen–progestogen therapy (EPT) regimen
(sequential or continuous) was available for 61% of EPT users
in EPIC7 and missing in E3N8. Data on adherence to medica-
tion, prescription and diagnostic bias were not assessed.
While E3N only included EPT users with oral MP, EPIC did not
differentiate between oral, vaginal and transdermal MP appli-
cation. MP dosage was not reported in both, EPIC and E3N.
Mean duration of EPT use was 2.5 years in EPIC (irrespective
of progestogen constituent)7, and 4.2 years in users of MP-
containing EPT in E3N8. During follow-up, 6017 and 3018 inci-
dent endometrial cancers were reported (e.g. self-report,
population cancer registries, health insurance records). Tumor
histology was reported in EPIC7 (not in E3N) and tumor stage
in E3N8 (not in EPIC). In current users of MP-containing EPT,
there were 26 endometrial cancer cases in EPIC (2231 non-
cases) and 54 cases in E3N (number of non-cases not given).
Current use of MP-containing EPT was associated with a
significantly increased risk of endometrial cancer in both,
EPIC (hazard ratio (HR) 2.42; 95% confidence interval (CI)
1.53–3.83)7 and E3N (HR 1.96; 95% CI 1.41–2.73)8. The
impact of treatment duration was only analyzed in E3N,
showing an increased risk after more than 5 years of use
but not below8. Endometrial cancer risk was not assessed
in respect to tumor histology, specifically to hormone
dependency or independency of the tumor. There is only
one 4-year RCT, the Kronos Early Estrogen Prevention Study
(KEEPS), comparing oral sequential MHT containing MP
(200mg/day) to placebo9. The incidence of endometrial
cancer was assessed as an adverse event. There was no
significant difference in endometrial cancer cases between
MHT users (n¼ 3) and placebo (n¼ 0).
Vaginal application of MP
The effect of vaginal MP on the endometrium has been
assessed by TVUS5,27–36, endometrial biopsy23,27–39 and endo-
metrial cancer incidence40 (Table 3).
Endometrial thickness
Endometrial thickness measured by TVUS was assessed in 11
studies5,27–36 of which four were RCTs5,27,28,34. In RCTs, vaginal
MP was either compared at different dosages5,28,34 or to intra-
uterine LNG27. The sample size ranged from 2032,36 to 13629
postmenopausal women, and treatment duration from 21
days32 to 3 years33. Estrogens were either applied as a vaginal
ring27,28, orally in standard dose29, or transdermally in stand-
ard dose5,27,29,31,33–36 and low-dose30. Vaginal MP was applied
as either a capsule or gel at different dosages ranging from
45mg/day29,31, 100mg/day5,27,30,33,35,36 to 200mg/day5,32,35 or
as a vaginal ring28,34. Application regimens were either
sequential (7–12 days/month)5,27,29, intermittent29–31,33,35,36 or
continuous28,32,34. The method of endometrial thickness
assessment was described by six authors only5,27,30,32,33,35.
Endometrial thickness was measured at the maximal thickness
of the endometrium in the longitudinal plane of the uterus,
specified as double layer in some studies27,30,35. In most stud-
ies, endometrial thickness remained unchanged with a
sequential (45mg/day29, 100mg/day27, 200mg/day5) or inter-
mittent (100mg/day30,33,36,35, 200mg/day35) regimen. In con-
trast, three studies reported a significant increase of
endometrial thickness with a sequential (100mg/day5), inter-
mittent (45mg/day31) or continuous (vaginal MP ring34).
Endometrial histology
Endometrial histology was assessed by biopsy in 14 stud-
ies23,27–39 of which five were RCTs27,28,34,38,39. In RCTs, vaginal
MP was either compared at different dosages28,34,39 to oral
MPA or transdermal norethisterone sacetate (NETA)38 or to
intrauterine LNG27. Baseline biopsies were performed in all
but four studies32,33,36,37. In few studies, endometrial biopsies
were only performed if indicated (e.g. suspect TVUS, uterine
bleeding)28–30. Endometrial biopsy procedure was described
by all authors. The majority either used a pipelle de
322 P. STUTE ET AL.
Cornier28,30,32,34 or performed a hysteroscopy-guided tar-
geted biopsy29,33,36,38. Others used a Novak’s curette31,37,
needle aspiration (pistolet method)23,35, Gynoscan method27
or vabra endometrial biopsy39. The sample size ranged
from 937 to 13629 postmenopausal women, and treatment
duration from 21 days32 to 3 years33. Systemic estrogens at
high37, standard23,27,29,31,33–36,38,39 or low30 dose were
applied either orally29,39, transdermally23,27,29–31,33–38 or vagi-
nally27,28. Vaginal MP was applied as a capsule or as gel at
different dosages ranging from 45mg/day29,31,39, 90mg/
day39, 100mg/day23,27,30,33,35–38 to 200mg/day23,32,35, as
intramuscular injection32 or a vaginal ring28,34. Application
regimens were either sequential (7–12 days/month)27,29,37,38,
intermittent23,29–31,33,35,36,39 or continuous28,34. Treatment
success22 was reported by the majority of studies, yielding
a predominantly atrophic (intermittent MP 45mg/day31,
sequential or intermittent MP 100mg/day30,33,36,27,38, MP
vaginal ring28,34) or secretory (intermittent MP 45–90mg/
day39, sequential37,38 or intermittent MP 100–200mg/
day23,36 endometrial response. Treatment failure22 was
reported by three studies showing some proliferative endo-
metrial responses (MP vaginal ring34, sequential or intermit-
tent MP 100–200mg/day35,38). Only one study reported a
hyperplastic endometrium in 10% of women after 1 year
without remarkable difference between groups (sequential
vaginal MP cream 100mg/day, oral MPA 10mg/day, or
transdermal NETA 0.25mg/day)38.
Endometrial cancer incidence
There was only one 5-year RCT, Early versus Late Intervention
Trial with Estradiol (ELITE), comparing sequential MHT con-
taining vaginal MP (45mg/day) to placebo40. The incidence of
endometrial cancer was assessed as an adverse event. There
was no significant difference in endometrial cancer cases
between MHT users and placebo (preliminary data presented
at World Congress of International Menopause Society,
Cancun, 2014).
Transdermal application of MP
Five studies have been identified investigating the impact of
transdermal MP on the endometrium41–45 (Table 4). All but
one study43 were RCTs, some of which had placebo41 or a
progestin42 as comparator. Sample size ranged from 2744,45 to
5443 postmenopausal women, and study duration from 441 to
4843 weeks. Estrogens were applied either orally41,42 or trans-
dermally43–45 with the dosage falling either within the high-
dose44,45 or moderate-dose41–43 category46. Transdermal MP
cream was applied either sequentially41,44,45 or continu-
ously42,43, and the dosage ranged from 16mg/day to 64mg/
day44,45. Transvaginal ultrasound for endometrial thickness
assessment was only performed in one study43 showing a sig-
nificant increase when combining estrogens with transdermal
MP cream. Endometrial biopsy was performed by all studies
comparing pre- and post-treatment histology. While two stud-
ies indicated an adequate progesterone opposing effect41,42,
the remainder did not43–45. There were two cases of complex
hyperplasia43 but no endometrial cancer was found.
Discussion
Current international guidelines on MHT recommend to
combine a progestogen when using estrogen therapy in
peri- and postmenopausal women with an intact uterus for
endometrial protection2,47–49. Progestogen addition should
be continuous or sequential for at least 12 days per month,
as recently again pointed out by the US Endocrine Society.
However, long-term endometrial safety of sequential pro-
gestogen addition may be reduced since the combination
of estrogens with MP (or dydrogesterone) is associated
with an increased risk of endometrial cancer if used for
more than 5 years48. Yet, compliance, dosage and route of
application of MP were not exactly known. Internationally,
systemic MP is available at different dosages and routes of
application. Also, indication and approval by regulatory
authorities may differ from country to country. In Europe,
systemic MP is available as a capsule (100mg, 200mg) for
vaginal or oral application or as vaginal gel (8% corre-
sponding to 90mg).
During the last years, the debate about (compounded) bio-
identical hormones has increased tremendously50–52.
Therefore, the aim of this international expert group was to
provide recommendations on the use of estrogens combined
with MP in postmenopausal women in respect to endometrial
safety.
The European Medicines Agency (EMA) recommends endo-
metrial biopsies at baseline and study closure as the gold-
standard method for evaluation for endometrial hyperplasia
during MHT53. Per definition, a biopsy is evaluable if there is
’endometrial tissue sufficient for diagnosis’. Endometrial biop-
sies should be classified into the general classes of atrophic,
proliferative, secretory, hyperplasia without atypia, hyperplasia
with atypia, cancer and others. Biopsies with insufficient tis-
sue for diagnosis may be categorized as ’atrophic endomet-
rium’ if the sonographic endometrial thickness is <5mm. For
a new MHT, combination studies of at least 12 months’ dur-
ation are required. The upper limit of the 95% confidence
interval of the incidence of hyperplasia or carcinoma should
not exceed 2% after 1 year, requiring a sample size of 300
patients.
For oral MP, there are only three RCTs following EMA’s
guideline15,18,22 All studies used sequential (12–14 days/
month) MP at 200mg/day for either 1.518,22 or 315 years.
When comparing sequential CMA (10mg/day) to sequential
MP (200mg/day), CMA provided a more complete progesto-
genic transformation18,22. However, according to the PEPI trial,
sequential MP (200mg/day) provided adequate endometrial
protection for up to 3 years, comparable to sequential or con-
tinuous MPA15. When further taking into account the results
from KEEPS (sequential MP at 200mg/day for 4 years)9 and
E3N8, the panel concluded that in postmenopausal women
combining estrogens with sequential (12–14 days/month) oral
MP at 200mg/day (EMA approval) for up to 5 years provides
sufficient endometrial protection. If oral MP is to be applied
continuously, the initial dosage should also be 200mg/day.
This dose may be lowered off-label to 100mg/day if an (ultra-)
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For vaginal MP, no study completely followed EMA’s
guideline and gained approval as an adjunct to meno-
pausal estrogen therapy. However, six studies investigated
vaginal MP for at least 1 year and performed endometrial
biopsies at baseline and at study closure23,27,31,35,36,38.
Vaginal MP (45–200mg/day) was applied either sequentially
(7–12 days/month)27,38 or intermittently (25 days/
month)23,35,36. The majority of investigators concluded that
sequential vaginal MP (100–200mg/day) was insufficient to
produce an adequate endometrial response23,35,36,38. When
taking into account long-term studies (3–5 years)33,40, the
use of sequential or intermittent vaginal MP does not seem
to increase the risk of endometrial hyperplasia or cancer.
However, due to the heterogeneity of studies and lack of
sufficient data, the panel concluded that in postmenopausal
women combining estrogens with sequential (4% corre-
sponding to 45mg/day on 10 days per month) or intermit-
tent (100mg every other day) vaginal MP for up to 3–5
years may be safe (off-label use). However, 4% MP vaginal
gel is not available on the European market. Finally, the
use of transdermal MP for endometrial protection cannot
be recommended in postmenopausal women using estro-
gen therapy.
It remains difficult to interpret these data as there is a
broad variety in study designs in terms of dosage per cycle,
route of administration, clinical findings, sample size per
protocol and even histological readings. Therefore, oral MP at
200mg daily for at least 12 days per month is the preferred
route, dose and duration for postmenopausal women with an
intact uterus when using estrogen therapy for up to 5 years
due to the currently available data. This conclusion seems to
be applicable also for the vaginal treatment route. However,
this procedure remains off-label use.
Conclusion
Postmenopausal women with an intact uterus using estrogen
therapy should receive a progestogen for endometrial protec-
tion. International guidelines on MHT do not specify on pro-
gestogen type, dosage, route of application and duration of
safe use. Based on a systematic literature review on MP for
endometrial protection, an international expert panel’s recom-
mendations on MHT containing MP are as follows: (1) oral MP
provides endometrial protection if applied sequentially for
12–14 days/month at 200mg/day for up to 5 years; (2) vagi-
nal MP may provide endometrial protection if applied
sequentially for 10 days/month at 4% (45mg/day) or every
other day at 100mg/day for up to 3–5 years (off-label
use); (3) transdermal MP does not provide endometrial
protection.
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